Project to Catalyze Cutting-Edge Research and Advance New York’s Leadership in Cell and Gene Therapy
View Renderings Here
NEW YORK – Governor Kathy Hochul yesterday announced plans for New York BioGenesis Park (NYBGP), a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub that will position New York as a global leader in CGT research, development, and innovation. New York Blood Center Enterprises (NYBCe), through its Comprehensive Cell Solutions (CCS) division, is proud to join this transformative initiative as a key partner. CCS will provide advanced expertise and infrastructure as a leading Contract Development and Manufacturing Organization (CDMO), supporting early-stage developers, pharmaceutical companies, and academic institutions. The project, in collaboration with the Albanese Organization as the developer, underscores NYBCe’s commitment to driving innovation in life sciences.
Located in Nassau County and bolstered by a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP will accelerate the translation of groundbreaking therapies from the lab to patients across New York’s diverse communities. This state-of-the-art facility aims to establish New York as a premier global destination for CGT innovation, driving economic growth, attracting top-tier talent, and revolutionizing patient care.
“We’re not just advancing medical science,” said Governor Hochul in an announcement on Tuesday. “We’re creating a powerhouse that will drive our economy, generate thousands of high-skilled jobs, and bring hope to millions facing life-threatening diseases.”
Christopher D. Hillyer, MD, President and CEO of NYBCe, added: “The establishment of the Long Island Center for Cell and Gene Therapy is a pivotal investment in the future of medicine. NYBCe and CCS are honored to play a leading role in positioning New York as a global leader in life sciences, particularly in cell and gene therapy, offering hope to patients with diseases once considered untreatable.”
Cell and gene therapies represent a new frontier in medicine, modifying a patient’s cells or genes to fight diseases at their source. These groundbreaking treatments offer new possibilities for previously incurable conditions —including cancers, genetic disorders, and autoimmune diseases—by targeting illnesses at the cellular and genetic levels. The advancements in these therapies could reshape the future of healthcare, unlocking new pathways for personalized medicine and offering hope to patients who have exhausted traditional treatment options.
“Today’s announcement goes beyond a new life science development; it establishes New York as a global leader in cell and gene therapy,” said Ayanna Bryan, Senior Director of Comprehensive Cell Solutions. “The Long Island Center for Cell and Gene Therapy will be a beacon of innovation, providing new hope for patients facing some of the world’s most challenging diseases.”
“This initiative will remove barriers to enable unique scientific and business collaboration, leverage the expertise of the best and the brightest minds at NYBC, CCS, and our esteemed partners across the state,” said Jay Mohr, Executive Vice President and Chief Business Officer, head of the CCS business unit at NYBCe. “We thank Governor Hochul and all participating organizations for their unwavering dedication to building a brighter, healthier future for patients and families across New York and beyond.”
New York Blood Center Enterprises (NYBCe) and Comprehensive Cell Solutions have been at the forefront of more than 60 years of lifesaving research, innovation, and impact. NYBCe is a vital community lifeline dedicated to serving patients and advancing global public health by providing blood products, cellular therapies, specialty pharmacy, and medical services to over 400 hospitals and 200 research, academic, and biomedical organizations.
About New York Blood Center Enterprises
Founded in 1964, New York Blood Center Enterprises (NYBCe) has provided more than 60 years of lifesaving research, innovation, and impact. NYBCe is one of the largest nonprofit blood centers, spanning 17+ states and serving 75 million people. NYBCe operates Blood Bank of Delmarva, Community Blood Center of Kansas City, Connecticut Blood Center, Memorial Blood Centers, Nebraska Community Blood Bank, New Jersey Blood Services, New York Blood Center, and Rhode Island Blood Center, delivering one million blood products to 400+ U.S. hospitals annually. NYBCe additionally delivers cellular therapies, specialty pharmacy, and medical services to 200+ research, academic, and biopharmaceutical organizations. NYBCe’s Lindsley F. Kimball Research Institute is a leader in hematology and transfusion medicine research, dedicated to the study, prevention, treatment and cure of bloodborne and blood-related diseases. NYBCe is a vital community lifeline dedicated to helping patients and advancing global public health. To learn more, visit nybce.org. Connect with us on Facebook, X, Instagram, and LinkedIn.
About Comprehensive Cell Solutions
Comprehensive Cell Solutions (CCS), a business unit of New York Blood Center Enterprises, is a cell and gene therapy-focused development and manufacturing organization that provides critical capacity to early-stage developers, as well as expertise and strategic footprint for hospital treatment centers and pharmaceutical organizations. Headquartered in New York, CCS provides a true Draw-to-Thaw™ solution, spanning fresh cellular collections and cord-blood derived stem cells as source material, to cell isolation, manipulation and cryopreservation capabilities for preclinical to commercial stage products. CCS boasts a client roster composed of the world’s leading pharmaceutical companies, innovative biotechnology organizations and academic medical centers. CCS also performs cellular collections, clinical apheresis and CGT manufacturing services.